No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HCAT240517C5000
- 1.85
- -0.15-7.50%
15min DelayClose May 16 15:59 ET
1.85High1.80Low
1.80Open2.00Pre Close8 Volume49 Open Interest5.00Strike Price1.46KTurnover332.38%IV0.28%PremiumMay 17, 2024Expiry Date2.03Intrinsic Value100Multiplier1DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9671Delta0.0534Gamma3.43Leverage Ratio-0.0198Theta0.0002Rho3.32Eff Leverage0.0003Vega
Intraday
- 5D
- 1D
News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Health Catalyst First Quarter 2024 Earnings: EPS Misses Expectations
Health Catalyst Inc (HCAT) Q1 2024 Earnings: Modest Revenue Growth and Strategic Financial ...
Health Catalyst | 10-Q: Quarterly report
Health Catalyst Is Maintained at Overweight by Wells Fargo
Health Catalyst Is Maintained at Overweight by Wells Fargo
Wells Fargo: Maintaining the Health Catalyst (HCAT.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $14.00 to $13.00.
Wells Fargo: Maintaining the Health Catalyst (HCAT.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $14.00 to $13.00.